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Mature dendritic cells (DCs) are established as unri-
valed antigen-presenting cells (APCs) in the initiation
of immune responses, whereas steady-state DCs
induce peripheral T cell tolerance. Using various
genetic approaches, we depleted CD11c+ DCs in
mice and induced autoimmune CNS inflammation.
Unexpectedly, mice lacking DCs developed aggra-
vated disease compared to control mice. Further-
more, when we engineered DCs to present a CNS-
associated autoantigen in an induced manner, we
found robust tolerance that preventeddisease,which
coincided with an upregulation of the PD-1 receptor
on antigen-specific T cells. Additionally, we showed
that PD-1 was necessary for DC-mediated induction
of regulatory T cells.Our results show that a reduction
of DCs interferes with tolerance, resulting in
a stronger inflammatory response, and that other
APC populations could compensate for the loss of
immunogenic APC function in DC-depleted mice.
INTRODUCTION
Experimental autoimmune encephalomyelitis (EAE) is a T cell-
mediated autoimmune disease of the CNS and is widely
used as a multiple sclerosis model (Gold et al., 2006). EAE is
induced by priming and expanding CD4+ T cells using CNS-
derived myelin antigens, which are normally sequestered264 Immunity 37, 264–275, August 24, 2012 ª2012 Elsevier Inc.behind the blood-brain barrier (Zamvil and Steinman, 1990). It
is not known exactly which antigen-presenting cells (APCs)
are responsible for activating these autoreactive T cells.
Dendritic cells (DCs) are considered prototypic APCs (Ban-
chereau and Steinman, 1998; The´ry and Amigorena, 2001). In
the absence of inflammation or infection, most DCs in periph-
eral tissues and lymphoid organs have a resting, immature
phenotype, characterized by high endocytic capacity and low
surface expression of major histocompatibility complex
(MHC) and costimulatory molecules. However, upon interaction
with microbial ligands, proinflammatory cytokines, or CD40
ligand, DCs rapidly acquire an activated phenotype and
become proficient in activating naive T cells (Steinman et al.,
2003).
DCs are sparse in a healthy CNS and are primarily found in
vessel-rich areas, such as the meninges and choroid plexus
(Anandasabapathy et al., 2011; Greter et al., 2005). CNS inflam-
mation induced by an autoimmune response or infection is
accompanied by entry of DCs into the CNS (Matyszak and Perry,
1996; Serafini et al., 2000). These CNS DCs, but not resident
microglia or infiltrating macrophages, are the most efficient
APCs in driving the reactivation of transferred myelin-specific
CD4+ T cells (Greter et al., 2005).
In addition to their proinflammatory role, DCs also promote
immune homeostasis by inducing and maintaining peripheral
T cell tolerance (Steinman and Nussenzweig, 2002). In contrast
to the naturally occurring regulatory T (nTreg) cells developing
in the thymus, induced Treg (iTreg) cells are generated in
the periphery, and DCs appear to play an essential role in their
development and maintenance (Darrasse-Je`ze et al., 2009;
Kretschmer et al., 2005; Yamazaki et al., 2008).
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DC-Independent Induction of EAEWe recently established that animals that constitutively lack
classical CD11chi DCs display unimpaired thymic negative
selection, but that the absence of DCs triggers a progressive
myeloproliferative disorder (Birnberg et al., 2008). As a result of
this disorder, DC-less mice develop signs of lymphocyte hyper-
activation. Moreover, Ohnmacht et al. (2009) reported that
animals lacking DCs succumb to a spontaneous fatal autoim-
mune disorder. In line with the above, a recent report uncovered
a direct correlation between DC numbers and Treg cells as part
of a feedback-control mechanism (Darrasse-Je`ze et al., 2009).
In this study, we show that depletion of DCs, either from birth
or later in adulthood, did not prevent EAE induction, but instead
led to a lower state of tolerance and stronger inflammatory
responses. We also show that DCs are responsible for the upre-
gulation of PD-1 on antigen-specific T cells and subsequently
induce the de novo conversion of Treg cells from naive T cells
during immune responses.
RESULTS
Targeted Expression of MOG to DCs Results
in Peripheral Tolerance and Prevention
of CNS Inflammation
In order to elucidate the role of DCs in maintaining and control-
ling autoimmune CNS inflammation, we opted for a system
that allows us the inducible and specific expression of an
autoantigen by DCs. We therefore crossed the tamoxifen
(TAM)-inducible CD11c-CreERT mice (Probst et al., 2003) to
the IiMOG mice (Frommer et al., 2008), resulting in animals in
which theMOG35-55 peptide is expressed as a CLIP replacement
peptide upon injection with TAM (iDCMOG mice, Figure S1A
available online). Upon TAM treatment, about 5% of all CD11c+
cells present the MOG peptide all over the body (Probst et al.,
2003). As seen in Figure 1A, iDCMOG mice were resistant to
EAE induction when DCs were forced to express the MOG
peptide following TAM injection 2 days prior to active immuniza-
tion, confirming previous studies that showed that steady-state
DCs induce tolerance (Bonifaz et al., 2002; Jiang et al., 1995;
Probst et al., 2003). Importantly, we discovered that the tolero-
genic effect was maintained even when TAM was administered
2 days after disease induction (Figure 1B), a time point at which
strong DC activating and maturation signals as well as the first
T cell priming had already taken place. At the same time, TAM
injection of wild-type (WT) animals had no adverse effect on
EAE development (Figure 1B). These findings show that MOG-
presenting DCs can downmodulate EAE even after the initial
priming phase of the disease. Furthermore, we investigated
whether EAE can be moderate if peptide presentation by DCs
is induced at a later time point. Remarkably, we found that
TAM injection 7 days after disease induction completely blocked
any signs of EAE (Figure 1C). To study whether the presentation
of MOG by DCs directly influences effector T (Teff) cells, we
induced EAE in mice, treated them with TAM after 7 days, and
isolated their splenocytes and reactivated them in vitro with
MOG 14 days later. Then, we gated on CD40 ligand+ (CD40L)
Teff cells. CD40L is rapidly expressed after activation and can
therefore serve as a marker for MOG-specific Teff cells (Fig-
ure 1D, left) (Chattopadhyay et al., 2005). As seen in Figure 1D,
the percentage of interleukin-17A (IL-17A)-producing cells andcells that coproduce IL-17A and interferon-g (IFNg) was sig-
nificantly reduced in TAM-treated iDCMOG mice compared to
control mice. Thus, our findings are consistent with the emerging
evidence that antigen-expressing DCs can inactivate memory
T and Teff cells (Kenna et al., 2008).
To elucidate the molecular mechanism of DC-induced toler-
ance, we transferred carboxyfluorescein succinimidyl ester
(CFSE)-labeled Thy1.1+ MOG35-55-specific CD4
+ 2D2 T cells
into Thy1.2+ iDCMOG mice and analyzed their proliferation and
expression of tolerance-associated cell surface molecules.
Although the 2D2 T cells proliferated when injected into TAM-
treated iDCMOGmice (Figure 1E), we found a strong upregulation
of PD-1 and a moderate elevation of BTLA on these cells
compared to 2D2 T cells transferred to control mice (Figure 1F).
Injection of anti-CD40 was previously shown to activate DCs
and shift the balance from tolerance to immunity (Probst et al.,
2003). We found that 14 and 21 days after transfer, 2D2 T cells
were still present in control mice injected with CD40-specific
antibodies, but we could not detect these cells in the iDCMOG
mice (Figure S1B). To investigate whether we could force DCs
to become immunogenic, we injected iDCMOG mice with TAM,
anti-CD40, complete Freund’s adjuvant (CFA), pertussis toxin
(PTx), or various combinations of these stimuli. As seen in Fig-
ure 1G, only when mice were injected with a combination of
CFA, anti-CD40, and PTx in addition to TAM treatment did half
of them develop signs of EAE (maximal score of 2.5). The latter
shows that once DCs are properly activated, they can revert
from inducing T cell tolerance to driving pathogenic T cell
responses. To test whether the low EAE incidence results from
Treg cell induction, iDCMOG mice were treated with TAM,
injected with isotype control (HRPN) or anti-CD25 antibody
(PC61) 7 days later, and immunized with MOG-CFA after an
additional 7 days. Although PC61 treatment could restore EAE
induction, the clinical score remained moderate (Figure 1H).
Next, we transferred naive 2D2 (eGFP) cells isolated from
2D2-FoxP3-eGFP reporter mice and analyzed their BTLA and
PD-1 expression by FoxP3 or FoxP3+ T cells. We found that
FoxP3+ cells exhibit elevated expression levels of BTLA and
PD-1 regardless of the host mice. However, in FoxP3 cells,
these molecules were upregulated only when 2D2 cells were
transferred into iDCMOG mice (Figures S1C and S1D).
The observation that presentation of autoantigen by steady-
state DCs could completely prevent EAE, whereas disease
induction could occur solely when activated DCs express the
self-peptide, suggests that a physiological function of steady-
state DCs is crucial for the induction and/or maintenance of
self-tolerance.
Conventional DCs Are Dispensable for the Induction
of CNS Inflammation
To further analyze the role of DCs in EAE induction, we utilized
our previously described inducible diphtheria toxin receptor
(iDTR) model, which, when crossed to the CD11c-Cre line
(Buch et al., 2005; Caton et al., 2007), allows the ablation of
DCs. Depletion of DCs in CD11c-iDTR mice is achieved by
injection of diphtheria toxin (DT, Figure S2A). Following 3 DT
injections, we reached a prolonged DC reduction of more than
94% in the spleen and about 80% in the lymph nodes (LNs) (Fig-
ure S2B), including both CD8a+ and CD8a DCs (Figure S2C),Immunity 37, 264–275, August 24, 2012 ª2012 Elsevier Inc. 265
Figure 1. Antigen Presentation by DCs Induces Tolerance to EAE and Expression of Coinhibitory Molecules on T Cells
(A–C) EAE was actively induced by immunization with MOG35-55-CFA in iDC
MOG or control mice. TAM was injected 2 days before (A), 2 days after (B), or 7 days
after (C) EAE induction.
(D) Splenocytes taken from EAE-afflicted mice (shown in C) were cultured in the presence of MOG35-55 for 6 hr. Three hr after MOG stimulation, Brefeldin A was
added. CD90.2+CD4+CD44+CD40Lhi-gated cells (Teff cells) were then analyzed for their expression of IFNg and IL17A (left), and percentages of IFNg+, IL17A+ or
IFNg+IL17+ Teff cells were calculated (right).
(E and F) Naive CFSE-labeled Thy1.1+ 2D2 CD4+ T cells were adoptively transferred to Thy1.2+ control or iDCMOG mice. Four days after transfer, mice were
injected with TAM, and 5 days later, cells were monitored for proliferation or for the expression of coinhibitory molecules. Shown are Thy1.1+-gated cells.
(G) iDCMOG and control mice were treated with CFA, TAM, and/or anti-CD40 (50 mg/mouse), as indicated in the table below. TAM and anti-CD40 were injected i.p.
2 days before subcutaneous injection of CFA (day 0). PTx was given to all mice on days 0 and 2. Mice that were not treated with TAM or anti-CD40 received oil or
PBS, respectively. Mice were observed daily for clinical signs of EAE. Data are representative of two or more independent experiments (nR 4 mice per group,
maximal clinical score 2.5).
(H) iDC-MOG mice were treated with TAM to induce MOG presentation by immature DCs. Seven days later, the mice were injected with either PC61 or HRPN.
Following another 7 days, the mice were immunized with MOG-CFA and disease was monitored for an additional 24 days (n = 5 mice/treatment).
EAE area under curve (AUC) was used to determine statistical significance via Student’s t test. Statistical analysis of splenic T cells was assessed via one-way
ANOVA; Newman-Keuls test. *p% 0.05, **p% 0.005, ***p% 0.0005; n.s., not significant. Error bars represent the mean ± SEM.
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Figure 2. Absence of DCs Is Permissive to EAE Induction and Enhances EAE Severity
(A–C) EAE was induced by immunization of MOG35-55 emulsified in CFA in CD11c-iDTR or iDTR mice (A and B), as well as in C57BL/6/C57BL/6 or CD11c-
DTR/C57BL/6 BM chimeric mice (C). Mice were subjected to DT injection (green arrows) at days 0, 3, and 6 (A),3, 0, and 3 (B), or5,2, 1, 4, 7, and 10 (C) of
EAE induction (5–9 mice per group).
(D) CNS-infiltrating cells were isolated using a Percoll gradient. Shown is a representative dot plot of CNS-infiltrating IFNg- and IL17A-producing CD4+ T cells, as
well as the calculated cell numbers (shown is a representative experiment [of four] with nR 7 mice/group).
(E) Passive EAE. WT mice were immunized with MOG-CFA, and 10 days later, splenocytes were isolated and cultured in the presence of MOG peptide under
conditions favoring Th1 or Th17 cell differentiation. Four days later, 5 3 106 blasting T cells were adoptively transferred i.v. into the indicated mice, and disease
progression was monitored for an additional 22 days. (Shown is a representative EAE graph of two individual experiments. Th1 cell nR 5 mice/group, Th17 cell
nR 11 mice/group.)
EAE AUC was used to determine statistical significance via Student’s t test. *p % 0.05, **p % 0.005, ***p % 0.0005; n.s., not significant. Error bars represent
the mean ± SEM.
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DC-Independent Induction of EAEwhereas plasmacytoid DCs (pDCs) essentially remained unaf-
fected (Figure S2D). Additionally, staining of epidermal sheets
for MHC class II showed effective depletion of Langerhans cells
(Figure S2E).
Surprisingly, when EAE was induced in DC-depleted CD11c-
iDTR mice, disease severity increased in comparison to control
littermates (Figure 2A). This difference became even more
apparent in experiments wherein control mice developed onlymild EAE (Figure 2B). When we analyzed the inflammatory
CNS infiltrates, we found no major differences in CD4+ T cell
frequencies (CD11c-iDTR 23.0% versus iDTR 21.1%). DCs
returned to 25% of their numbers in the control group 72 hr after
the last DT injection. Due to adverse toxic side effects of using
CFA, PTx, and DT together (Meyer Zu Ho¨rste et al., 2010), which
impaired our scoring, we had to discontinue DT injections 6 days
post immunization (dpi). As a result, the amounts of DCs in theImmunity 37, 264–275, August 24, 2012 ª2012 Elsevier Inc. 267
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DC-Independent Induction of EAECNS were similar in both sets of mice at 14 dpi (CD11c-iDTR
8.8% and iDTR 10.7%).
To compare the effect of DC ablation on EAE using a more
established system, we turned to the CD11c-DTR mice (Jung
et al., 2002). As these mice die upon repetitive DT injections
(Zaft et al., 2005), we prepared bone marrow (BM) chimeric
mice wherein the host was CD45.1 WT and the donor BM was
either CD45.2 WT or CD45.2-CD11c-DTR. Similarly to the find-
ings using CD11c-iDTR mice, we found that DC ablation before
and after immunization resulted in enhanced EAE (Figure 2C). In
line with the elevated disease score, analysis of CNS infiltrates
confirmed higher numbers of CD4+ T cells infiltrating the inflamed
CD11c-DTRCNS, as well as higher numbers of both single-posi-
tive IFNg+ and IL-17A+CD4+ T cells (Figure 2D). Importantly,
these elevated total numbers of T helper 1 (Th1) and Th17 cells
reflect thehigher infiltrates, andnot a change in ratio of thesecells
among the CD4+ T cells. To exclude the potential toxicity of DT
and the role of CFA as a potent adjuvant, we performed adop-
tive-transfer EAE using WT T cells (Figure 2E). In accordance
with our previous results, MOG-primed Th1 cells induced a
stronger disease when transferred into DC-less mice (Figure 2E,
top). Similarly, the transfer of MOG-primed Th17 cells into DC-
less mice also resulted in a stronger disease following the first
days of disease onset. Interestingly, 6 days after the first signs
of EAE, the DC-less mice showed reduced clinical scores as
compared with control mice (Figure 2E, bottom). This reverted
EAE may reflect the previously reported function of DCs as
indispensable APCs in the CNS during EAE (Greter et al., 2005).
To circumvent the inherent problemwith using DT in combina-
tion with active immunization, we used a third system in which
DCs are continuously ablated by crossing the CD11c-Cre mice
to Rosa-DTA mice (Birnberg et al., 2008; Brockschnieder et al.,
2004). In these animals, termed CD11c-DTA, DT is expressed
specifically in DCs, leading to constitutive ablation of CD11c+
cells as of birth (Figure S3A). In accordance with our previous
results, we found that these mice exhibited somewhat higher
disease scores compared to control littermates (Figure S3B).
This difference was not statistically significant, possibly due to
the high individual variability in these mice. The clinical EAE
scores of the CD11c-DTA mice tie in well with the histological
analyses, showing similar degrees of demyelination, APP, and
infiltration/activation of macrophages/microglia as well as T
and B cells in DC-proficient mice compared with DC-less mice
(Figures S3C–S3E). Taken together, our data demonstrate that
DCs are dispensable for the induction of EAE, and their function
can be carried out by other MHC class II+, CD11c APCs.
Neither Plasmacytoid DCs nor B Cells Overtake the Role
of DCs in the Induction of Autoimmune Response
pDCs can replace the priming function of DCs in LNs after
ablation of conventional DCs, and they have been shown to
contribute to EAE development (Sapoznikov et al., 2007) (Isaks-
son et al., 2009). Given that pDCs were only partially affected
in the CD11c-iDTR (Figure S2D) and CD11c-DTA mice (Birnberg
et al., 2008), we combined the CD11c-iDTR system with a
depleting antibody specific to pDCs (anti-mPDCA-1). When we
injected the mice with the antibody, they were devoid of pDCs
and DCs (Figure S4A) but still developed EAE similar to mice
that lacked only DCs (Figure S4B).268 Immunity 37, 264–275, August 24, 2012 ª2012 Elsevier Inc.Recently, it has been reported that granulocyte macro-
phage colony-stimulating factor (GM-CSF)-dependent CD103+
CD207+ dermal DCs are crucial for EAE induction (King et al.,
2010). These cells are MHC-IIhi and CD11c+ and are present in
both the dermis and draining LNs. Our peripheral lymphoid stain-
ing showed near-complete absence of MHC-IIhiCD11c+ cells in
DC-less mice (Figure S2B). A careful examination of skin
(including both epidermis and dermis) from the CD11c-DTR BM
chimeras revealed nearly complete loss of these dermal
CD103+CD207+ DCs, which did not influence the host-derived
radio-resistant epidermal Langerhans cells (Figure S5A), indi-
cating that although these cells are sufficient for EAE induction,
they are not needed for it and can be replaced by other APCs.
Apart fromDCs, macrophages and B cells are also considered
professional APCs. To test which cells may present antigen in
the absence of DCs, we immunized the mice with fluorescent
microbeads emulsified with CFA. We then analyzed which cells
took up the beads and migrated to the draining LNs. In the
absence of DCs, the beads are confined to B cells and macro-
phages (Figure S5B). As complete macrophage ablation is not
possible, because it leads to death of the mice (Heppner et al.,
2005), we were not able to perform such an experiment. B cells,
on the other hand, can be ablated using anti-CD20 antibodies
(Po¨llinger et al., 2009). We could not find any effect of the B
cell depletion on the course of EAE when DCs were also ablated
(Figure S5C). In contrast, in DT-treated control mice, depletion of
B cells enhanced the disease, as shown previously for B cell-
deficient mice (Figure S5D) (Fillatreau et al., 2002). These exper-
iments demonstrate that in the absence of DCs, antigen presen-
tation is performed by macrophages or other CD11clow/ cells.
DCs Control T Cell Proliferation and Expression
of BTLA and PD-1 in Response to Antigen
We have shown that the interaction of T cells with tolerizing DCs
results in upregulation of both PD-1 and BTLA expression
(Figure 1F). As PD-1 expression is strongly associated with
tolerance (Fife and Bluestone, 2008; Probst et al., 2005; Wais-
man and Yogev, 2009) and BTLA is a negative costimulatory
molecule (Han et al., 2004; Watanabe et al., 2003), we tested
whether the expression of these molecules upon immunization
would be affected by DC ablation. To this end, we transferred
Thy1.1+ CFSE-labeled 2D2 CD4+ T cells into MOG-immunized,
DT-treated Thy1.2+ CD11c-iDTR or CD11c-DTA mice and
analyzed cell proliferation and surface expression of BTLA and
PD-1 5 days later. Remarkably, 2D2 T cell proliferation was
enhanced in mice in which DCs were conditionally depleted or
missing from birth (Figures 3A and 3B, respectively). Importantly,
2D2 cells upregulated PD-1 and BTLA only when transferred to
DC-proficient animals (Figures 3C and 3D). Because the pro-
liferation of 2D2 cells was even stronger in the absence of
DCs, the upregulated PD-1 and BTLA expression is not a mere
sign of activation, but indeed a clear indication of a specific inter-
action of DCs with CD4+ T cells that leads to the upregulation
of these tolerance-associated molecules.
Steady-State DCs Exhibit their Suppressive Capacity
by Promoting the Development of iTreg Cells
Because our data indicated that the tolerogenic effect of DCs is
present in the priming phase, we analyzed the differentiation of
Figure 3. Proliferation of 2D2 Transgenic T cells Is Enhanced in the
Absence of DCs In Vivo
(A and B) Naive CFSE-labeled 2D2 Thy1.1+ T cells were transferred i.v. into
MOG35-55-CFA-immunized iDTRmice and compared to CD11c-iDTRmice (A),
or into DTA mice compared to CD11c-DTA littermates (B–D) (all recipient mice
were Thy1.2+). Five days later, cells were isolated from the draining LNs and
proliferation was assessed by flow cytometry.
(C and D) Surface expression levels of the inhibitory molecules BTLA (C) and
PD-1 (D) on the transferred Thy1.1+CD4+ 2D2 T cells. Data are representative
of three independent experiments with no fewer than three mice per group.
The respective mean fluorescence intensity (MFI) values in the marked region
are indicated by color.
Error bars represent the mean ± SEM.
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DC-Independent Induction of EAECD4+ T cells 8 days after immunization. Despite the fact that
CD11c-DTA mice lacked DCs (Figure 4A), we did not find
discrepancies in Th1 or Th17 cell differentiation at this time point
(Figure 4B). However, we observed a significantly lower number
of Foxp3+ T cells in spleens of DC-depleted animals (Figure 4C).
Given that this finding may explain the higher degree of EAE
severity, we analyzed Treg cells from CD11c-DTR BM chimeras
12 days after EAE induction, and, once more, we found a signif-
icant reduction in the number of Treg cells in the spleen, but not
in the LNs (Figure 4D, left). Moreover, we observed that Treg cells
in these animals expressed significantly lower Foxp3 levels
compared to those of control mice (Figure 4D, middle). Nonim-
munized, DT-treated BM chimeras showed comparable
numbers of Treg cells (Figure 4D, right). Additionally, messenger
RNA (mRNA) expression for both Foxp3 and transforming
growth factor b (TGF-b) were strongly reduced (Figure 4E). To
assess the induction of bona fide Treg cells by DCs in vivo, naive
CD45.1+GFP T cells were isolated from FoxP3-eGFP mice
(Korn et al., 2007) and transferred into either CD45.2+ WT or
CD11c-DTR BM reconstituted mice. Prior to T cell transfer, the
BM chimeric mice were subjected to DT injection. A day later,
the mice were immunized, and 7 days later, the newly generated
iTreg cells were assessed (Figure 4F). In line with the previous
data, iTreg cells differentiated much more efficiently when DCs
were present, showing that, indeed, de novo Treg cell differenti-
ation is disturbed in the absence of DCs during immunization.
Numerous publications had shown that DCs are responsible
for both nTreg and iTreg cell differentiation (for a review, seeKushwah and Hu, 2011). To assess whether, in our model,
Treg cells expand in the presence of or contract in the absence
of DCs, we transferred naive Thy1.1 2D2-Foxp3(eGFP) T cells
into Thy1.2 host CD11c-DTA or DTA mice and analyzed the ratio
of endogenous and transferred Treg cells. As expected,
following immunization, we found increasing numbers of host-
derived (i+n) Treg cells in the presence of DCs (Figure 5). Never-
theless, DC-proficient mice displayed higher percentages and
total (i+n) Treg cell numbers compared with DC-deficient mice
(Figures 5A, 5B, 5D, and 5E). When gating on the transferred
Thy1.1+ cells and analyzing GFP+ cells, we noticed that DC-defi-
cient mice had far less iTreg cell conversion than control mice
(Figures 5A, 5C, 5D, and 5F). Similar results were obtained
when the cells were transferred into the CD11c-DTR BM system
(Figure 5G). Taken together, our results demonstrate that
steady-state DCs are essential in the conversion of naive
T cells to iTreg cells in the process of immune responses.
DCs Guide the Development of Treg Cells via PD Ligand
Interaction with PD-1 Expressed by T Cells
Naive CD11c-DTA mice harbor normal numbers of Treg cells
(Birnberg et al., 2008). We assumed that the lower number of
Treg cells found in immunized CD11c-DTA and CD11c-DTR
animals are due to insufficient induction of Treg cells after EAE
induction, shown previously (Korn et al., 2008). To test this
hypothesis, we coincubated WT splenic APCs, which were
depleted of DCs, with naive 2D2 cells, MOG peptide, and
TGF-b. In agreement with our finding of lower Treg cell numbers
in DC-depleted immunized mice, in vitro DC-depleted APCs
were considerably less efficient in inducing Foxp3+ Treg cells
compared to DC-containing APCs (Figures 6A and 6B). Not
only were the Treg cell numbers reduced, but we also found
decreased Foxp3 protein expression in the absence of DCs
(Figure 6C). When coculturing Treg cells isolated from either
DC-proficient or DC-deficient mice with 2D2 cells and MOG-
pulsed BMDCs, we noticed that the 2D2 cells showed reduced
proliferation in the presence of DC-proficient derived Treg cells
(Figure 6D). Hence, not only does the loss of DCs results in
reduced Treg cell conversion and lower expression levels of
Foxp3, it also translates into reduced suppression.
As PD-1 signaling was recently demonstrated to favor the
development of iTreg cells (Francisco et al., 2009), we hypothe-
sized that the higher PD-1 expression by T cells in the presence
of DCs may favor iTreg cell development, leading to reduced
EAE. We therefore tested whether PD-1 expression on T cells
was necessary for DC-mediated Treg cell induction. Thus, we
used naive 2D2-PD-1ko T cells and performed a similar experi-
ment, as described in Figure 6. Interestingly, we found that
PD-1ko T cells did not respond to the presence of DCs with
higher iTreg cell differentiation, whereas PD-1-sufficient T cells
did (Figure 7A). In line with these experiments, we found that
DCs are a major population of PD-L1 expression, which is lost
upon depletion of DCs in BM chimeric CD11c-DTR mice and in
the other DC-less models (Figure S6). To assess the functional
implication of the lower expression of the PD-1 ligands, we
tested whether PD-1 ligands were able to restore the iTreg cell
induction. Indeed, the combination of PD-L1 and PD-L2, when
added as recombinant proteins linked to Fc, fully complemented
the lacking DCs in inducing Treg cells (Figure 7B). These findingsImmunity 37, 264–275, August 24, 2012 ª2012 Elsevier Inc. 269
Figure 4. Immunization of Mice Lacking
DCs Results in Reduced Treg Cell Number
(A–C) The indicated mice were immunized with
MOG35-55-CFA and analyzed 8 days later for the
presence of DCs, Foxp3+, IL-17A, and IFNg-
producing T cells.
(A) Analysis showing the absence of splenic DCs
(CD11chi) in the DTA system.
(B) Percentages of IFNg single-producing or IL-
17A single-producing CD4+ cells (designated Th1
and Th17, respectively) in the draining LNs.
(C) Percentages of CD4+ Foxp3+ Treg cells in the
spleenofMOG35-55-CFA-immunizedmice. (DTA
+/,
n = 3; CD11c/DTA+/, n = 3.) Data are representa-
tive of at least three independent experiments.
(D) Percentage of Treg cells as found in the spleen
or LNs of immunized BM chimeric CD11c-DTR
mice on day 12 after EAE induction (BM: C57BL/6,
n = 4; BM: CD11c-DTR, n = 3) (left). Foxp3
expression as measured by MFI in Treg cells of
LNs and spleens of the latter mice (middle).
Percentage of Treg cells or DCs found in spleen or
LNs of DT-treated BM chimeric CD11c-DTR or
C57BL/6 mice 8 days after first DT treatment (BM:
C57BL/6, n = 5; BM: CD11c-DTR, n = 5) (right).
(E) Real-time mRNA analysis of splenocytes
from DT-treated BM chimeric animals 5 days
after immunization (BM: C57BL/6, n = 5; BM:
CD11c-DTR, n = 4). Data are representative of
three or more independent experiments.
(F) MACS-purified CD45.1+GFP naive CD4+
T cells were transferred into CD45.2+ BM chimeric
mice previously injected with DT (BM: C57BL/6,
n = 9; BM: CD11c-DTR, n = 9). DT was applied
every second day, starting from day 6 until
day +4 post immunization. dLN, draining LN.
Statistical analysis was assessed using Student’s
t test or one-way ANOVA; Newman-Keuls test.
*p % 0.05, **p % 0.005, ***p % 0.0005; n.s., not
significant. Error bars represent the mean ± SEM.
Immunity
DC-Independent Induction of EAEsuggest that DCs induce Treg cells via a PD-1-dependent
mechanism, and thereby contribute to tolerance. Next, we
cotransferred 2D2 and 2D2-PD-1ko T cells into iDCMOG (Fig-
ure 7C) or CD11c-DTA mice (Figure 7D) and assessed the role
of PD-1 in Treg cell differentiation in vivo. Consistent with our
previous observations, we found higher percentages of 2D2
Treg cells in iDCMOG mice compared to control mice. Similarly,
2D2-PD-1ko Treg cells were increased in the iDCMOG mice,
though to a lesser degree (Figure 7C). A further dissection re-
vealed higher numbers of both 2D2 Foxp3+ and IFNg+ cells,
but not IL-17A+ cells (Figures 7E–H). When CD11c-DTA mice
were used, we saw that the lack of DCs resulted in lower
percentages of 2D2 Treg cells (Figure 7D). Moreover, Treg cell
percentages were comparable between 2D2 Treg cells in
CD11c-DTA mice and 2D2-PD-1ko Treg cells in DTA mice (Fig-
ure 7D), thus confirming our in vitro data.
Treg cell suppression needs to be tightly controlled and, there-
fore, believed to take place in the target tissue. Because we
found an enhanced autoimmune response that was associated
with reduced numbers of Treg cells, we tested whether Treg cell
numbers in the CNS were also reduced. As seen in Figure S7,
thenumbersofCNS-infiltratingTregcellswere indeeddiminished
in the CNS of DC-depleted mice compared with control mice.270 Immunity 37, 264–275, August 24, 2012 ª2012 Elsevier Inc.DISCUSSION
In this paper, we demonstrated that induction of EAE through
immunization with MOG35-55 in CFA was possible in mice that
possessed less than 5% of the normal number of DCs. Remark-
ably, DC-less mice developed more severe EAE compared to
mice with normal DC numbers, suggesting that during immuni-
zation, DCs reduce the responsiveness of CD4+ T cells to self-
antigens, including those sequestered in the CNS. We identified
PD-1-dependent induction of MOG35-55-specific Treg cells by
antigen-presenting DCs as a crucial mechanism underlying
reduced T cell responsiveness and susceptibility to EAE.
Furthermore, our results suggest that either the number of
mature DCs required for priming is extremely low, or other
APC types, most likely CD11c, are sufficient for EAE induction.
Interestingly, we could show that even when T cells were
adoptively transferred to DC-less mice, disease was enhanced
in the first few days, although at the later stage of the disease
it became milder. These findings have two conclusions: first,
that even without active immunization, Treg cells (that develop
from the transferred cells or host cells) play an important
role in disease development, and second, that once disease
is in its peak, CNS DCs are important for maintenance of the
Figure 5. Reduced Treg Cell Numbers in the Absence of DCs
(A–F) 53 106 naive Thy1.1+ 2D2-Foxp3-eGFP transgenic T cells were transferred into the indicatedmice and one day later the mice were immunized withMOG-
CFA. Eight days after cell transfer, inguinal LN and splenic Treg cells (A–C and D–F, respectively) were assessed based on the expression of congenic markers,
eGFP, and Foxp3 expression. Endogenous (i+n) Treg cells = host-derived Thy1.2+Foxp3+ cells, whereas de novo iTreg cells = Thy1.1+eGFP+ cells. Treg cell
conversion was set to maximal based on the immunized DTA mice, and all other groups were calculated relative to that (A and D); absolute cell numbers are
shown in (B), (C), (E), and (F). Data are representative of two independent experiments; n = 3 mice per group.
(G) Similar experiment to that described above (A–F), except that the recipient mice in this case are the CD11c-DTR or C57BL/6 BM chimeric mice.
Error bars represent the mean ± SEM.
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DC-Independent Induction of EAEfull-blown clinical manifestations, as shown before (Greter et al.,
2005).
CD11c-positive DCs are bona fide APCs inducing CD4 and
CD8 T cell responses upon immunization (Sapoznikov et al.,
2007) and have been implicated in thymic negative selection
(Brocker et al., 1997). However, recent studies using DC-less
mice showed that both thymic and peripheral T cell repertoire
are not affected by the loss of DCs (Birnberg et al., 2008). Never-
theless, these experiments confirmed the importance of splenic
and thymic DCs for inducing mixed lymphocyte alloreactions
and the formation of antiviral T cell immune responses (Birnberg
et al., 2008). Indeed, ovalbumin-specific T cells did not react to
systemic antigen in spleens upon depletion of DCs, but, surpris-
ingly, these T cells reacted strongly in the LNs to subcutaneous
immunizations with antigen, despite a lack of DCs (Birnberg
et al., 2008). This DC-independent T cell activation in the LNs
may explain the efficient MOG peptide-specific T cell activation
in DC-lessmice reported in this paper. Our experiments, in whichboth DCs and pDCs were depleted, imply the possibility that
cells other than DCs act as primary APCs in the LNs when DCs
are absent. B cells and macrophages are both potential candi-
dates. In the case of B cells, it has been shown that they are
not mandatory for EAE induction with the MOG peptide, as B
cell-deficient animals develop a severe, chronic form of EAE
(Fillatreau et al., 2002; Wolf et al., 1996). In addition, a role for
B cells was recently shown in multiple sclerosis, as it was found
that B cell depletion with anti-CD20 has a profound positive
effect in patients with multiple sclerosis (Hauser et al., 2008).
We have shown that ablation of both DCs and B cells does not
prevent the disease induction, which suggests that a possible
non-DC myeloid population is sufficient for T cell priming. These
data either point to a strong redundancy between the distinct
DC populations or the presence of another (as yet) undiscovered
CD11c APC as the main priming cell type in EAE. However, we
cannot exclude the possibility that the residual numbers of DCs
are sufficient to prime T cells in LNs.Immunity 37, 264–275, August 24, 2012 ª2012 Elsevier Inc. 271
Figure 6. Impaired Induced Treg Cell Differ-
entiation and Suppression in the Absence
of DCs
(A and B) MACS-purified naive CD4+ 2D2 trans-
genic T cells were differentiated using TGF-b at
indicated concentrations in the presence of
MOG35-55 and cocultured with either WT total
splenic APCs or WT splenic APCs depleted of
DCs, using MACS beads. Cells were FACS-
analyzed by CD4 and Foxp3 staining. Percentages
of CD4+Foxp3+ cells are indicated.
(B) Percentages of Foxp3+ of total live CD4+ cells
are summarized in the diagram.
(C) Differences in the MFI of CD4+Foxp3+ T cells
are shown by histograms. The respective MFI
values of cells in the marked region are indicated
by color. Data are representative of four inde-
pendent experiments.
(D) MFI of the CFSE-labeled 2D2 cells upon co-
culturing withMOG-pulsed BMDCs and Treg cells
isolated from either MOG-immunized DC-less or
control mice 10 days post immunization.
Error bars represent the mean ± SEM.
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DC-Independent Induction of EAEA recent paper showed that CD103+CD207(langerin)+ dermal
DCs are crucial for EAE induction (King et al., 2010). These cells
are MHC-IIhi and CD11c+ and are present in both the dermis and
in the draining LNs. Our staining showed nearly complete
absence of MHC-IIhiCD11c+ cells in DC-less mice. Moreover,
a careful examination of skin (including both epidermis and
dermis) from the CD11c-DTR BM chimeras revealed nearly
complete loss of these dermal CD103+CD207+ DCs without
influence on the host-derived radio-resistant epidermal Langer-
hans cells. The disparity of EAE development in the two models
could be explained by the concurrent depletion of tolerogenic
steady-state DCs in our system, which may lower the threshold
for EAE induction and therefore circumvent the need for
CD103+CD207+ dermal DCs in EAE induction. In line with this,
our DC-less CD11c-iDTR mice showed an absence of CD8+
DCs, which are most notably implicated in tolerance induction
(Yamazaki et al., 2008).
Similarly, as described previously (Birnberg et al., 2008), we
found enlargements of the spleen and LNs in aged CD11c-DTA
mice (data not shown), but not a strong autoimmune lympho-
proliferative infiltration with a fatal autoimmune syndrome, as
reported by others (Ohnmacht et al., 2009). This distinct
outcome may be explained by different housing hygienic con-
ditions, as our data point to a strong role of DCs in the formation
of adaptive Treg cells, which may be crucial in controlling the
immune response against viral or bacterial infections. Naive,272 Immunity 37, 264–275, August 24, 2012 ª2012 Elsevier Inc.nonimmunized CD11c-DTA mice harbor
an unimpaired thymic Treg cell com-
partment and numbers of splenic Treg
cells similar to those of WT animals.
Here, we show that, upon immunization,
CD11c-DTA and DT-treated BM chimeric
CD11c-DTR mice display a reduced
number of Treg cells in the spleen in com-
parison to WT animals. We think that
this finding indicates a role of DCs in theinduction of Treg cells. This is in line with previous findings that
immunization induces a substantial amount of novel antigen-
specific Treg cells (Korn et al., 2008; Kretschmer et al., 2005).
Indeed, when we transferred naive T cells before immunization,
we observed a strong reduction of iTreg cell differentiation in
the absence of DCs. Our in vitro Treg cell induction experiments
and in vivo analysis of Foxp3 expression fully support this role of
DCs, because naive T cells differentiated considerably better
into Foxp3+ cells in the presence of DCs. The iTreg cells that
developed in the presence of DCs also expressed higher
Foxp3 levels than those that developed in the absence of DCs.
High expression of Foxp3 is shown to promote a full Treg cell
program and an enhanced suppression profile by Treg cells
(Williams and Rudensky, 2007). In addition, we found that Treg
cells isolated from DC-less mice were less efficient in T cell
suppression compared to those isolated from WT mice.
Together, these data suggest that Treg cells depend on DCs
for full phenotypic and functional development.
When we transferred naive antigen-specific T cell receptor
(TCR)-transgenic T cells to immunized CD11c-DTA mice, we
discovered that they did not upregulate PD-1 expression when
compared with cells transferred to control mice, in spite of
a strong and even enhanced proliferative response. These
findings suggest that DCs are involved in the programming of
gene expression in T cells in a unique manner, i.e., not shared
by other APCs. Although we do not fully understand the precise
Figure 7. PD-1 Expression on T Cells Is
Required for Induced Treg Cell Differentia-
tion by DCs
(A) MACS-purified naive CD4+ T cells from either
2D2 or 2D2-PD-1ko transgenic mice were differ-
entiated using TGF-b at the indicated concentra-
tions in the presence of MOG35-55 and cocultured
with WT T cell-depleted total splenic APCs or
APCs additionally depleted for DCs.
(B) Recombinant PD-L1 and PD-L2 Fc-fusion
proteins complement the lack of DCs for iTreg cell
development in vitro. Naive CD4+ 2D2 T cells were
cultured under iTreg cell-polarizing conditions
(TGF-b = 1 ng/ml) together with total splenic APCs,
DC-depleted splenic APCs, or DC-depleted
splenic APCs supplemented with recombinant
PD-L1 (5 mg/ml) and PD-L2 (10 mg/ml). Data are
representative of three independent experiments.
(C) 2D2 and 2D2-PD-1ko cells were cotransferred
into TAM-treated iDCMOG or control mice, and
comparative in vivo Treg cell conversion was
assessed.
(D) Similar experiment to (C), performed in CD11c-
DTA or DTA mice.
(E–H) Transferred cells, as shown in (C), were
analyzed for total cell numbers; Treg, Th1, and
Th17 cell subsets (C–H, nR 3 mice per group).
Error bars represent the mean ± SEM.
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DC-Independent Induction of EAEmechanism by which DCs induce tolerance, prime candidates
are distinct costimulatory pathways or cytokine milieus in the
presence of DCs. We propose that, upon PD-1 cell surface
expression, signaling via PD-L1 and PD-L2 is enhanced, leading
to a primary tolerogenic program and differentiation of antigen-
specific T cells to Foxp3+ regulatory cells. The latter is in line
with our findings that Treg cell development is dependent on
PD-1 expression by T cells, as seen in experiments wherein
PD-1-deficient T cells were transferred to WT or DC-less mice.
Furthermore, we found that DCs express high levels of PD-L1,
indicating that one major PD-L1-expressing population vanishes
upon depletion of DCs in immunized animals. A recent publi-
cation (Amarnath et al., 2010) shows in a xenogenic transfer
system that the transfer of humanDCs, whichwere preincubated
with Treg cells, induced the upregulation of PD-1 on Teff cells.
Due to the fact that this depended on PD-L1 being expressedImmunity 37, 264–275on these tolerogenic DCs, it is conceiv-
able that PD-L1 signaling in a tolerogenic
positive feedback loop leads to PD-1
upregulation on T cells.
Here, we show that EAE can be
induced in the absence of classical DCs.
Furthermore, our data confirm that DCs
are important tolerance mediators for
CD4+ T cell responses. Given that sub-
stantial numbers of PD-L1hi DCs are
found in the spleen, we favor the follow-
ing scenario: T cells are first primed by
DCs or other cells in the draining LNs.
After priming, T cells migrate to the
spleen and are modulated there by DCs.Depending on the initial priming strengths, this second phase
of modulation dictates whether immunity or tolerance prevails.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice were obtained from Jackson Laboratories. CD11c-Cre (Caton
et al., 2007), DTA (Brockschnieder et al., 2004), CD11c-CreERT (Probst
et al., 2003), liMOG (Frommer et al., 2008), iDTR (Buch et al., 2005), PD-1ko
(Nishimura et al., 1999), and 2D2 (Bettelli et al., 2003) mice have been previ-
ously described. All mice were housed in specific pathogen-free conditions
and used in accordance with the guidelines of the Central Animal Facility
Institution of the University of Mainz.
Depletion of Dendritic Cells and B cells
For in vivo DC depletion, mice were injected intraperitoneally (i.p.) with 25 ng/g
body weight DT. DC depletion during EAE was carried out following repetitive
DT injections. Generally, DT was applied every third day. To achieve in vivo, August 24, 2012 ª2012 Elsevier Inc. 273
Immunity
DC-Independent Induction of EAEpDC depletion, mice were injected with 0.5 mg followed by three consecutive
injections of 0.25 mg anti-mPDC-1 every 2 days. In vitro DC depletion: total
splenocytes were depleted of T cells and DCs (Thy1.2 andCD11c beads) using
MACS depletion columns. In vivo B cell depletion: mice were injected i.p. with
250 mg anti-CD20 (clone 18B12; IgG2a; Biogen Idec), kindly provided by
R. Dunn, or control IgG2a antibodies weekly, starting 14 days prior to MOG
immunization, and continuing until 6 dpi.
Induction and Assessment of EAE
EAE (active and passive) was induced and assessed as previously described
(Frommer et al., 2008).
Flow Cytometry Staining and Acquisition
Fluorescence-activated cell sorting (FACS) surface and intracellular antibodies
were purchased from eBioscience or BD Pharmingen and used in accordance
with the manufacturer’s protocol. Samples were acquired with FACS-Scan or
FACS Canto II.
Isolation of Splenic DCs and CNS Infiltrates
Spleens were incubated with 2 mg/ml Collagenase D for 30 min and then
mashed through a 70 mm cell strainer. CNS infiltrates were isolated as previ-
ously described (Greter et al., 2005). In brief, mice were perfused using
ice-cold PBS. The brain and spinal cords were removed and incubated in
PBS containing collagenase type II (2 mg/ml, GIBCO) and DNase (20 units,
Sigma-Aldrich). The tissue was then homogenized and loaded on a
30:37:70% Percoll gradient for enrichment of CNS infiltrates.
Tamoxifen Preparation and Administration
TAM (ICN Biomedicals, Aurora, OH, USA) was suspended in 96% EtOH,
diluted in olive oil (1:10 ratio; ICN Biomedicals). Prior to injection, the mixture
was further dissolved in 37C. Cre-recombinase activity of CD11c-CreERT
mice was induced in vivo by twice injecting i.p. 2 mg of TAM in 100 ml.
Adoptive T Cell Transfer and CFSE Labeling
Freshly isolated CD4+ T cells were washed twice with PBS (pH 7.4) and then
incubated with 0.5 mM CFSE (Molecular Probes, Eugene, OR, USA), as previ-
ously described (Frommer et al., 2008). For proliferation studies, enriched CD4
2D2 transgenic (Thy1.1+) T cells were CFSE-labeled, counted, and 7 3 106
cells-injected intravenously (i.v.) in PBS into MOG-CFA-immunized (Thy1.2+)
recipient mice. The mice were sacrificed 5 days after T cell transfer, and cells
were analyzed by flow cytometry.
In Vitro iTreg Cell Differentiation
1.5 3 105 MACS-purified naive CD4+ 2D2 transgenic T cells were cocultured
with 53 104 splenic APCs, 20 mg/ml MOG peptide, and TGF-b at the indicated
concentration. For intracellular Foxp3 detection, cells were stained with
a commercially available kit (eBioscience). Intracellular cytokine analysis
was performed after stimulation of T cells for 4 hr with phorbol 12-myristate
13-acetate (PMA, 100 ng/ml), Ionomycin (200 ng/ml), and Brefeldin A
(1 mg/ml). A commercially available kit was used for intracellular cytokine stain-
ing in accordance with the manufacturer’s protocol (BD Biosciences).
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and can be found with this
article online at http://dx.doi.org/10.1016/j.immuni.2012.05.025.
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